Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Roselli

Showing results (1-10 of 164) with videos related to

Pageof 17
Sort By:
World Journal of Gastroenterology|March 18, 2015
Targeted therapy in first line treatment of RAS wild type colorectal cancerVincenzo Formica, Mario Roselli
Cancer Biology & Therapy|March 11, 2015
Are there alternative ways to quantify the real benefit of novel agents in oncology? - the 'death pace'Vincenzo Formica, Eugenio Montefusco, Mario Roselli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2012
Family history of cancer in patients with gastric cancerVincenzo Formica, Enrico Vasile, Mario Roselli
Expert Review of Anticancer Therapy|August 30, 2013
Aging: an important risk factor in chemotherapy-associated vascular diseasesMario Roselli, Fiorella Guadagni, Patrizia Ferroni
Cancers|April 3, 2021
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in CancerPatrizia Ferroni, Fiorella Guadagni, Mario Roselli
Expert Opinion on Biological Therapy|May 22, 2018
Issues and promises of bevacizumab in prostate cancer treatmentVittore Cereda, Vincenzo Formica, Mario Roselli
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
VEGF and VTE Risk in Cancer Patients--LetterPatrizia Ferroni, Silvia Riondino, Fiorella Guadagni, et al.
Current Vascular Pharmacology|June 3, 2009
Thromboembolic events in patients treated with anti-angiogenic drugsPatrizia Ferroni, Vincenzo Formica, Mario Roselli, et al.
Anticancer Research|October 13, 2012
Perianal Paget's disease: a case report and literature reviewMatteo Vergati, Vincenzino Filingeri, Gianpiero Palmieri, et al.
International Journal of Cancer|June 7, 2018
Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice?Vincenzo Formica, Alberto Zaniboni, Fotios Loupakis, et al.
Pageof 17

Showing results (1-10 of 164) with videos related to

Sort By:
Pageof 17
World Journal of Gastroenterology|March 18, 2015
Targeted therapy in first line treatment of RAS wild type colorectal cancerVincenzo Formica, Mario Roselli
Cancer Biology & Therapy|March 11, 2015
Are there alternative ways to quantify the real benefit of novel agents in oncology? - the 'death pace'Vincenzo Formica, Eugenio Montefusco, Mario Roselli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2012
Family history of cancer in patients with gastric cancerVincenzo Formica, Enrico Vasile, Mario Roselli
Expert Review of Anticancer Therapy|August 30, 2013
Aging: an important risk factor in chemotherapy-associated vascular diseasesMario Roselli, Fiorella Guadagni, Patrizia Ferroni
Cancers|April 3, 2021
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in CancerPatrizia Ferroni, Fiorella Guadagni, Mario Roselli
Expert Opinion on Biological Therapy|May 22, 2018
Issues and promises of bevacizumab in prostate cancer treatmentVittore Cereda, Vincenzo Formica, Mario Roselli
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
VEGF and VTE Risk in Cancer Patients--LetterPatrizia Ferroni, Silvia Riondino, Fiorella Guadagni, et al.
Current Vascular Pharmacology|June 3, 2009
Thromboembolic events in patients treated with anti-angiogenic drugsPatrizia Ferroni, Vincenzo Formica, Mario Roselli, et al.
Anticancer Research|October 13, 2012
Perianal Paget's disease: a case report and literature reviewMatteo Vergati, Vincenzino Filingeri, Gianpiero Palmieri, et al.
International Journal of Cancer|June 7, 2018
Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice?Vincenzo Formica, Alberto Zaniboni, Fotios Loupakis, et al.
Pageof 17